Potentiating effect of the ATP-sensitive potassium channel blocker glibenclamide on complex I inhibitor neurotoxicity in vitro and in vivo

NeuroToxicology

Volumn 27, Issue 5, 2006, Pages 826-834

  Kou, Jinghong ^a   Klorig, David C ^a   Bloomquist, Jeffrey R ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

Dopamine transporter; Mitochondria; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; DINOSEB; DOPAMINE TRANSPORTER; GLIBENCLAMIDE; POTASSIUM CHANNEL BLOCKING AGENT; REACTIVE OXYGEN METABOLITE; ROTENONE; RUBIDIUM; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL PROTECTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; GENETIC DISORDER; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NEUROTOXICITY; NONHUMAN; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPTOSOME; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CALCIUM; COBALT; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTRON TRANSPORT COMPLEX I; GLYBURIDE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; NEUROTOXICITY SYNDROMES; POTASSIUM CHANNEL BLOCKERS; ROTENONE; TYROSINE 3-MONOOXYGENASE;

MURINAE;

EID: 33747164173     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2006.04.004     Document Type: Article

References (53)

1. Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P., Boyd A.E., Gonzalez G., et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268 (1995) 423-426
2. Arai N., Misugi K., Goshima Y., and Misu Y. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 515 (1990) 57-63
3. 2 elevation, not ATP depletion. J Neurosci 25 43 (2005) 10029-10040
4. Bartschat D.K., and Blaustein M.P. Potassium channels in isolated presynaptic nerve terminals from rat brain. J Physiol 361 (1985) 419-440
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 12 (2000) 1301-1306
6. Bougria M., Vitorica J., Cano J., and Machado A. Implication of dopamine transporter system on 1-methyl-4-phenylpyridinium and rotenone effect in striatal synaptosomes. Eur J Pharmacol 291 (1995) 407-415
7. 3H]dopamine release from synaptosomes is dependent on neuronal type Ca2+ channels and is not mediated by acetylcholine, glutamate or aspartate release. J Pharmacol Exp Ther 254 (1990) 664-670
8. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
9. Deffois A., Fage D., and Carter C. Inhibition of synaptosomal veratridine-induced sodium influx by antidepressants and neuroleptics used in chronic pain. Neurosci Lett 220 (1996) 117-120
10. Eastwood S.L., Burnet P.W., and Harrison P.J. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neurosci 66 2 (1995) 309-319
11. Edwards G., and Weston A.H. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 33 (1993) 597-637
12. Feldman J.M. Glyburide: a second generation sulfonylurea hypoglycaemic agent. Pharmacotherapy 5 (1985) 43-60
13. Ferger B., Eberhardt O., Teismann P., Groote C., and Schulz J.B. Malonate-induced generation of reactive oxygen species in rat striatum depends on dopamine release but not on NMDA receptor activation. J Neurochem 73 (1999) 1329-1332
14. + in rat brain synaptosomes and mitochondria. Brain Res 975 (2003) 214-221
15. Fosslien E. Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 31 1 (2001) 25-67
16. Gerlach M., Riederer P., Przuntek H., and Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 208 (1991) 273-286
17. 2+-permeable channel activated by changes in redox status confers susceptibility to cell death. Mol Cell 9 1 (2002) 163-173
18. Hasbani D.M., Perez F.A., Palmiter R.D., and O'Malley K.L. Dopamine depletion does not protect against acute 1-methyl-4-pheyl-1,2,3,6-tetrahydropyridine toxicity in vivo. J Neurosci 25 4 (2005) 9428-9433
19. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93 (1996) 1956-1961
20. Heikkila R.E., and Sonsalla P.K. The MPTP-treated mouse as a model of parkinsonism: how good is it?. Neurochem Int 20 Suppl (1992) 299S-303S
21. Hornykiewicz O., and Kish S. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45 (1987) 19-34
22. KATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 270 (1995) 1166-1170
23. +)-evoked dopamine release from rat striatal slices: possible roles of voltage-dependent calcium channels and reverse dopamine transport. Neurochem Int 39 3 (2001) 253-260
24. Innis R.B., Seibyl J.P., Scanley B.E., Laruelle M., Abi-Dargham A., Wallace E., et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 90 (1993) 11965-11969
25. Kou J., Gillette J.S., and Bloomquist J.R. Neurotoxicity in murine striatal dopaminergic pathways following co-application of permethrin, chlorpyrifos and MPTP. Pestic Biochem Physiol 85 (2006) 68-75
26. Lazdunski M. Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 28 (1996) 488-495
27. Lin Y.J., Greif G.J., and Freedman J.E. Multiple sulfonylurea-sensitive potassium channels: a novel subtype modulated by dopamine. Mol Pharmacol 44 (1993) 907-910
28. Liss B., Bruns R., and Roeper J. Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. EMBO J 18 4 (1999) 833-846
29. Liss B., Haeckel O., Wildmann J., Miki T., Seino S., and Roeper J. K-ATP channels promote the differential degeneration of midbrain dopaminergic neurons. Nat Neurosci 8 (2005) 1742-1751
30. + release and cellular efflux in ischemic and apoptotic neuronal death. J Neurochem 86 (2003) 966-979
31. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridium triggers intracellular dopamine oxidation. J Biol Chem 275 49 (2000) 38581-38588
32. 2+ channels in neurons by increasing protein tyrosine phosphorylation. J Biol Chem 277 27 (2002) 24368-24375
33. 3H]dopamine uptake into rat striatal synaptosomes. Biochem Pharmacol 63 (2002) 1499-1505
34. Marey-Semper I., Gelman M., and Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 5 (1993) 1029-1034
35. + channel in the guinea-pig substantia nigra. Exp Brain Res 110 (1996) 360-366
36. Moy L.Y., Xeevalk G.D., and Sonsalla P.K. Role for dopamine in malonate-induced damage in vivo in striatum and in vitro in mesencephalic cultures. J Neurochem 74 (2000) 1656-1665
37. + channel. Jpn J Physiol 41 (1991) 177-187
38. Nuydens R., Novalbos J., Dispersyn G., Weber C., Borgers M., and Geerts H. A rapid method for the evaluation of compounds with mitochondria-protective properties. J Neurosci Meth 92 1-2 (1999) 153-159
39. Patel M.N., Yim G.K., and Isom G.E. Potentiation of cyanide neurotoxicity by blockade of ATP-sensitive potassium channels. Brain Res 593 1 (1992) 114-116
40. Sakura H., Ammala C., Smith P.A., Gribble F.M., and Ashcroft F.M. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic β-cells, brain, heart and skeletal muscle. FEBS Lett 338 (1995) 338-344
41. Santiago M., Granera L., Machado A., and Cano J. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur J Neurosci 280 (1995) 251-256
42. Schapira A.H.V. Causes of neuronal death in Parkinson's disease. Adv Neurol 86 (2001) 155-162
43. Schapira A.H.V., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54 (1989) 823-827
44. 1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55 (1990) 2142-2145
45. Stephans S.E., Miller G.W., Levey A.I., and Greenamyre J.T. Acute mitochrondial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. NeuroToxicology 23 (2002) 569-580
46. Tai K.K., and Truong D.D. Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's disease. J Neurosci Res 69 (2002) 559-566
47. Takla P.G. Glibenclamide. In: Florey K. (Ed). Analytical profiles of drug substances (1981), Academic Press Inc., New York 337-356
48. Taylor S.C., Shaw S.M., and Peers C. Mitochondrial inhibitors evoke catecholamine release from pheochromocytoma cells. Biochem Biophys Res Commun 273 1 (2000) 17-21
49. Tillerson J.L., Caudle W.M., Reveron M.E., and Miller G.W. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol 178 (2002) 80-90
50. Tokube K., Kiyosue T., and Arita M. Effects of hydroxyl radicals on KATP channels in guinea-pig ventricular myocytes. Pflugers Arch 437 1 (1998) 155-157
51. Towbin G.O., Stachelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 (1979) 4350-4354
52. Waring P. Redox active calcium ion channels and cell death. Arch Biochem Biophys 434 (2005) 33-42
53. Wright A.M., Bempong J., Kirby M.L., Barlow R.L., and Bloomquist J.R. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res 788 (1998) 215-222